Strand Therapeutics, a Massachusetts Institute of Technology (MIT) spinout, has raised $153 million in a Series B funding round to accelerate its next-generation mRNA therapeutics platform. According to industry funding trackers, Strand’s raise is the third highest series B fund this year, following Tune Therapeutics and AIRNA. At a time when investors are pulling back due to concerns over pharmaceutical tariffs, research funding cuts, and leadership changes at public health agencies, Strand’s ability to secure one of the year’s biggest Series B funds signals strong confidence in its pioneering approach.
Strand’s pipeline is led by STX-001, a therapy designed to express the potent cytokine IL-12 (interleukin-12) directly within the tumor microenvironment (TME). Early Phase 1 clinical data presented at the 2025 ASCO annual meeting demonstrated multiple signs of efficacy, including complete and metabolic responses, along with prolonged disease stabilization and a favorable safety profile — even in treatment-resistant patients.
“Our initial STX-001 Phase 1 data provides early and strong clinical validation of our platform’s capabilities,” said Jake Becraft, CEO and co-founder of Strand Therapeutics. “We have observed systemic immune activation and anti-tumor responses, including responses in non-injected lesions, across multiple tumor types. Now is an exciting period of expansion for our existing clinical work, as well as the breakthrough assets in our pipeline, all with the potential to transform the treatment of cancer and other serious diseases.”
Overcoming the challenges associated with cytokines
Cytokines, like IL-12, are signaling proteins that act as the immune system’s messengers, capable of mobilizing a full-scale attack against cancer cells. IL-12 is a particularly potent cytokine that can supercharge anti-tumor responses, driving T helper 1 cell differentiation, enhancing the killing power of T and natural killer cells, and inducing high levels of interferon-gamma, which can itself kill tumor cells, cut off their blood supply, and make them more visible to immune attack.
In preclinical models, IL-12 has shown striking anti-tumor activity across a range of cancers. However, IL-12 therapies have repeatedly failed in patient studies. Previous trials showed that even low doses of IL-12 were intolerable, triggering dangerous cytokine storms that led to fever, severe immune dysregulation, and sometimes lethal outcomes. The problem wasn’t that IL-12 didn’t work; it was that it worked everywhere, unleashing inflammation far beyond the tumor.
Strand’s approach ensures that the therapy is localized rather than systemic. By using engineered mRNA that only switches on inside tumor cells, their therapy restricts IL-12 production to the TME. This local, durable expression recruits and activates the immune system precisely where it’s needed, avoiding the severe toxicities associated with systemic cytokine therapy. Localized delivery also holds another advantage: Sparking a targeted immune response at the tumor site may still generate systemic immunity, training the body to hunt down metastases without bathing the whole system in IL-12. The result is the potential for a more potent, safer, and longer-lasting anti-tumor immune response.
Programming RNA to ‘think’
Strand’s innovation lies in combining the power of IL-12 with a technology that precisely controls where and when it acts. The company’s mRNA constructs combine self-replication genes adapted from RNA viruses with genetically programmed logic circuits that control when, where, and how much therapeutic protein is expressed in the body.
These logic circuits allow Strand’s mRNAs to “sense” their cellular environment. By reading patterns of microRNA signatures, the mRNAs can distinguish between target and off-target cells. If inside the correct cells, they translate the encoded therapeutic protein. If inside the wrong cells, the mRNAs self-destruct, degrading before they can cause harm.
By integrating self-replication with these logic circuits, Strand can also sustain therapeutic protein expression locally, reducing the need for repeated dosing and ensuring that the immune system receives a consistent, tumor-targeted stimulus.
A new era for mRNA medicines
The success of mRNA vaccines during the COVID-19 pandemic proved that mRNA can be rapidly designed and manufactured.
Strand is now pushing the field into its next phase: programmable, long-acting, disease-responsive therapies. By combining synthetic biology, computational design, and novel RNA formats, the company is building medicines that can adapt in real time to disease signals, opening doors to treatments once thought impossible.
“We believe programmable RNA is the next frontier in therapeutics,” said Christian Scherrer, Senior Investment Director at Kinnevik, which led the investment round. “Strand has built the leading platform to unlock it. Their early clinical data is outstanding, and the systemic delivery capability has the potential to reshape how we treat disease, starting with cancer.”
For patients, this could mean safer and more effective options where few exist today. For medicine, it signals a future in which mRNA’s role expands beyond vaccine technology into a programmable therapeutic engine capable of addressing cancer, autoimmune conditions, and other intractable diseases.
